



**24 January 2018**

ASX Announcement

## **Race Receives \$170k R&D Tax Incentive Refund**

---

**24 January 2018: Race Oncology Limited ("RAC")** is pleased to announce it the Company has received a \$170,261.61 R&D Tax Incentive refund for the 2016/2017 financial year.

The R&D Tax Incentive is an important Australian Government Program that refunds up to 45% of eligible expenditure on research and development.

### **About Bisantrene**

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers. It has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race has filed two patents on the drug and has been granted an Orphan Drug Designation in the USA for AML, which confers seven years of market exclusivity in the US from the date of FDA approval.

### **About Race Oncology (RAC.ASX)**

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of pharmaceutical mergers.

### Media contact:

Heidi Cuthbert

+61 411 272 366

E: [heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)